Outcome of Board Meeting held on 14th May 2026 for declaration of Audited Financial Results (Standalone & Consolidated) of the Company for the period ended 31st, March, 2026
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mangalam Drugs & Organics reported a sharp deterioration in FY26 performance. Standalone revenue from operations fell to Rs 2,321.33 Lakhs from Rs 3,175.76 Lakhs in FY25 (approx 27% decline). The company swung to a standalone net loss of Rs 4,381.42 Lakhs versus a net profit of Rs 692.43 Lakhs in the prior year. Consolidated net loss stood at Rs 4,440.00 Lakhs. Operating cash flow remained positive at Rs 416.45 Lakhs (standalone). Inventories reduced significantly by Rs 3,602.82 Lakhs, while short-term borrowings increased by Rs 2,360.30 Lakhs. Auditors issued a clean report with no modified opinion. The company has a pending merger of its subsidiary Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited, with NCLT hearing scheduled for June 2, 2026.
The company swung to a significant loss in FY26 with a revenue decline of ~27%, indicating operational challenges. Short-term borrowing increased substantially, reflecting pressure on working capital. Shareholders should monitor the pending merger outcome and the company's ability to return to profitability.